A novel HSF1 activator ameliorates non‐alcoholic steatohepatitis by stimulating mitochondrial adaptive oxidation

Background and Purpose Non‐alcoholic steatohepatitis (NASH) is the more severe form of metabolic associated fatty liver disease (MAFLD) and no pharmacological treatment as yet been approved. Identification of novel therapeutic targets and their agents is critical to overcome the current inadequacy o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of pharmacology 2022-04, Vol.179 (7), p.1411-1432
Hauptverfasser:	Rao, Yong, Li, Chan, Hu, Yu‐Tao, Xu, Yao‐Hao, Song, Bing‐Bing, Guo, Shi‐Yao, Jiang, Zhi, Zhao, Dan‐Dan, Chen, Shuo‐Bin, Tan, Jia‐Heng, Huang, Shi‐Liang, Li, Qing‐Jiang, Wang, Xiao‐Jun, Zhang, Ying‐Jun, Ye, Ji‐Ming, Huang, Zhi‐Shu
Format:	Artikel
Sprache:	eng
Schlagworte:	activator AMP-Activated Protein Kinases - metabolism Animal models Animals Cell culture Cholesterol Chromatin Drug therapy Fatty liver Heat shock factors Heat Shock Transcription Factors - agonists Heat Shock Transcription Factors - metabolism High cholesterol diet High fat diet HSF1 activation HSF1 protein Immunoprecipitation Kinases Liver - metabolism Liver diseases Methionine Mice Mice, Inbred C57BL Mitochondria Mitochondria - metabolism mitochondrial adaptive oxidation Non-alcoholic Fatty Liver Disease - metabolism non‐alcoholic steatohepatitis Nutrient deficiency Oxidation Oxidative stress Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism Peroxisome proliferator-activated receptors PGC‐1α Protein kinase Therapeutic targets Transcription activation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!